Prevalence and level of antibodies anti-Plasmodium spp. in travellers with clinical history of imported malaria. by Atouguia, Jorge Luís Marques da Silva & Silva, Marcelo
Hindawi Publishing Corporation
Journal of Parasitology Research
Volume 2013, Article ID 247273, 5 pages
http://dx.doi.org/10.1155/2013/247273
Clinical Study
Prevalence and Level of Antibodies Anti-Plasmodium spp. in
Travellers with Clinical History of Imported Malaria
Rita Medina Costa, Karina Pires de Sousa, Jorge Atouguia,
Luis Távora Tavira, and Marcelo Sousa Silva
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In this study, we show that 40.29% of travellers with a possible history of malaria exposure were positive for anti-Plasmodium spp.
antibodies, while these individuals were negative by microscopy. The antibody test described here is useful to elucidate malaria
exposure in microscopy-negative travellers from endemic countries.
1. Introduction
Malaria is an infectious disease caused by a protozoan
parasite of the genus Plasmodium, which is transmitted
between humans by the bite of infected female Anopheles
mosquitoes. These parasites have a complex life cycle, both
in the invertebrate vector and vertebrate hosts. In the human
body, parasites multiply in hepatocytes, and then invade red
blood cells (RBCs), initiating blood stage infection, which
corresponds to the symptomatic period of the disease [1].
Malaria remains one of the most serious public health
problems not only in endemic countries, where 2 billion
people (approximately 40% of the world’s population) are
at risk of contracting the disease, but also in nonendemic
areas, where the increasing number of imported malaria
cases is worrying [2]. In developed countries, imported
malaria predominates in tourists and immigrants who travel
to their home countries to visit friends and relatives. Every
year, approximately 125 million international travellers visit
malaria endemic areas, and 30,000 of them contract the
disease [3, 4]. In Portugal, the occurrence of 50 such cases per
year [5] is estimated according to the National Public Health
System.
Following infection with any of the five species of Plas-
modium that are capable of infecting humans,P. falciparum,P.
ovale, P. vivax, P. malariae, and P. knowlesi, specific antibodies
are produced one or two weeks after the initial infection and
persist for three to six months after parasite clearance [6].
These antibodies may endure for months or years in semi-
immune patients in endemic countries where reinfection is
frequent. However, in a näıve patient, antibody levels fall
more rapidly. Reinfection or relapse leads to a secondary
response with a high and rapid rise in antibody titres [6, 7].
Thus, in the present study, we aim to evaluate the
prevalence and the level of anti-Plasmodium spp. antibodies
in serum samples from travellers with possible clinical signals
and symptoms ofmalaria. Using an ELISA-based commercial
immunoassay kit to measure antimalarial antibodies, we
determined the raw serological profile of these individuals.
Additionally, we compare the latter serological profile with
the gold-standard laboratory diagnosis, based on direct
microscopy.
2. Materials and Methods
2.1. Study Population. Thepopulation for this study consisted
of 335 individuals with possible clinical history ofmalaria and
23 healthy individuals (healthy Portuguese individuals who
have never been inmalaria-endemic countries). All of the 435
subjects who have had potential exposure to Plasmodium spp.
travelled back to Portugal from malaria-endemic regions of
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Africa, Brazil, Ecuador, India, Indonesia,Thailand, andHaiti,
either as residents or tourists, and most of them are adults.
Subjects for this study were actively recruited after being seen
for symptoms of malaria at the Clinical Unit for Tropical
Diseases (IHMT, Portugal).
Following microscopic examination of Giemsa-stained
blood films, subjects who were potentially exposed to the
parasite and had concomitant positive microscopy were
categorized into group 1 (𝑛 = 45); subjects potentially
exposed to the parasite but displayed negative microscopy
were categorized into group 2 (𝑛 = 290); and finally, healthy
näıve subjects were categorized into group 3 (𝑛 = 23).
2.2. Microscopic Diagnosis of Malaria. From each patient
was obtained blood by venipuncture (5mL of blood in
anticoagulant), and two blood smears were prepared (thick
and thin blood films). The haematological data was obtained
from an automatic Coulter Sysmex K-1000 analyzer (Emı́lio
de Azevedo Campos). Both blood films were stained by
Giemsa’s staining method and were observed on an optical
microscope. The thick blood film was used to attain a
qualitative diagnosis for malarial infection, and the thin
blood film was used to identify the Plasmodium species,
when infection was present. Moreover, when infection was
established, the thin blood film was also used to count the
number of parasites in 200 leucocytes, and this number was
then converted to number of parasites in one microliter of
blood [8]. Samples with no visible parasites after scoring
100 fields were considered to be negative for this test. These
procedures were used as the diagnostic test for malaria. This
clinical study protocol was approved by the Institutional
Ethics Committee of the Instituto de Higiene e Medicina
Tropical, Universidade Nova de Lisboa, Portugal (clinical
study registration 4, 2012, PN, February 2012).
2.3. Serological Measurement of Antimalarial Antibodies.
Total anti-Plasmodium spp. (antimalarial) antibodies were
analysed from serum samples collected from all individuals
(𝑛 = 358). The Newmarket Laboratories Malaria EIA kit
(Bio-Rad, USA) was used in this study for evaluating the
prevalence of total antimalarial antibodies in the depicted
groups of subjects. This system is based on the binding of
anti-Plasmodium spp. antibodies (IgG, IgM, and IgA) by use
of four recombinant antigens that detect antigens from P.
falciparum, P. ovale, P. vivax, and P. malariae. The test was
performed as recommended by the manufacturer, as follows.
50𝜇L of individual undiluted sera samples were added in
each single well. For each assay plate, 50𝜇L of positive and
negative controls were also dispensed. The negative control
was tested in triplicate and the positive control in duplicates.
After mixing on a plate shaker for 30 seconds, the plate was
covered and incubated for 30 minutes at 37∘C before being
washed 5 times with wash buffer. 50𝜇L of diluted horseradish
peroxidase-conjugated antibodywere added to eachwell, and
the plates were incubated for 30 minutes at 37∘C. The wells
were washed again 5 times, and 50𝜇L of substrate solution
were added to each well. The plate was then covered and
incubated in the dark for 30 minutes. Finally, 50𝜇L of 0.5M
sulphuric acid were added to each well to stop the reaction,
and the absorbance was read at 450 nm, with a reference
wavelength of 620 nm. The antibody index was obtained by
dividing the OD value of each sample (at 490 nm) by the cut-
off value, which was calculated as the mean of the negative
control value plus 0.100, according to the manufacturer.
2.4. Data Analysis. After establishing the study groups, a
commercial immunoassay Malaria EIA kit (Bio-Rad, USA)
was used to determine total anti-Plasmodium spp. antibodies.
The Malaria EIA kit is based on presence of antibodies (IgM,
IgG, and IgA) reactive to four recombinant antigens to detect
P. falciparum, P. ovale, P. vivax, and P. malariae. The cut-
off value was calculated as the mean of the negative control
value plus 0.100. To validate the assay, the optical density
(OD) of each negative control should be lower or equal to
0.080, and the OD of each positive control should be greater
than or equal to 1.000. The antibody index was obtained by
dividing the OD value of each sample (at 490 nm) by the cut-
off value. The samples with indexes lesser than or equal to
1 were considered negative. Moreover, the samples with an
antibody index greater than 1 were considered positive for
the presence of antimalarial antibodies. This immunoassay
does not distinguish between IgG, IgM, and IgA antibodies,
or between antibodies to P. falciparum, P. vivax, P. ovale, and
P. malariae.
3. Results and Discussion
In this study, the prevalence and level of total antimalar-
ial antibodies (anti-Plasmodium spp.) were determined in
patients with possible clinical history of malaria. These
patients were actively recruited in the Clinical Unit for
Tropical Diseases (IHMT, Portugal). The malaria antibody
EIA (Newmarket, UK; Bio-Rad) is based on binding of
anti-Plasmodium antibodies present in a serum sample to
antigens immobilized on a solid phase. The antigens are
four recombinant types specific for P. falciparum with cross-
reactivity for P. ovale and P. malariae and one specific antigen
for P. vivax. The test detects total immunoglobulin (Ig)
antibodies against P. falciparum and P. vivax and shows 80%
cross-reactivity with P. ovale and 67% with P. malariae. The
malaria antibody EIAwas performed as recommended by the
manufacturer.
Table 1 shows the distribution and characterization of
two groups of individuals potentially exposed to Plasmodium
spp. based on microscopic diagnosis for malaria (blood
films), comparedwith a third group consisting of nonexposed
individuals.
Figure 1 and Table 1 show the distribution and level of
total antimalarial antibodies in three groups: group no.
1 (travellers potentially exposed to Plasmodium spp. and
microscopically positive for malaria), group no. 2 (travellers
potentially exposed to Plasmodium spp. and microscopically
negative for malaria), and group no. 3 (nonexposed indi-
viduals, healthy individuals who reside in Portugal). From
all individuals potentially exposed to Plasmodium spp. (𝑛 =
335), 13.43% (𝑛 = 45) had positive blood films. On the
Journal of Parasitology Research 3













Figure 1: Distribution of antimalarial antibodies in subjects with
possible clinical history of imported malaria. Antibody index rep-
resents the ratio OD/cut-off for each sample. Group no. 1: travellers
potentially exposed to Plasmodium spp. and microscopically posi-
tive for malaria (𝑛 = 45); group no. 2: travellers potentially exposed
to Plasmodium spp. and microscopically negative for malaria (𝑛 =
290); and group no. 3: control, healthy subjects (𝑛 = 23).
other hand, 40.29% (𝑛 = 135) had positive ELISA serological
reactions to Plasmodium spp. (Table 1). As expected, naı̈ve
individuals (group no. 3) had serological andmicroscopically
negative results to malaria.
Results regarding the prevalence and level of antimalarial
antibodies displayed by subjects in group no. 1 (positive blood
film) and group no. 2 (negative blood film) are detailed in
Figures 2(a) and 2(b), respectively. Both results are compared
with the ones from group no. 3 (nonexposed individuals).
Of all microscopically positive individuals (𝑛 = 45), 80%
(𝑛 = 36) showed some level of antimalarial antibodies
(Figure 2(a)). Furthermore, of all individuals microscopically
negative for malaria (𝑛 = 290), 34.1% (𝑛 = 127) had anti-
malarial antibodies and 65.9% (𝑛 = 191) had no serological
reaction to Plasmodium spp. (Figure 2(b)).
The use of immunofluorescence to determine the preva-
lence of antimalarial antibodies has been used to estimate
malaria endemicity [9, 10], but its use was limited by depen-
dence on cultured parasites, expensive fluorescence micro-
scopes, and the subjective nature of slide reading. However,
determination of antimalarial antibodies by ELISA has been
shown to be a potentially useful epidemiological tool [11, 12].
For example, antibodies to the circumsporozoite antigen have
been associated with transmission intensity [10] and with
cumulative (age related) exposure to infection in both Brazil
[13] and Sri Lanka [14]. In addition, serological data are
relatively simple to collect: blood processed or blood spots
collected. Processed blood or blood spots onto filter paper
are a suitable source of serum if appropriately collected and
stored [15, 16], and ELISA-based antibody assays are robust,
relatively low tech with high throughput and inexpensive.
However, antibody detection is not a substitute for blood
film examination in the diagnosis of an acute attack of
Table 1: Characterization of the individual groups used for the







Group no. 1 45 Positive Positive (𝑛 = 36)Negative (𝑛 = 9)
Group no. 2 290 Negative Positive (𝑛 = 99)Negative (𝑛 = 191)
Group no. 3 23 Negative Positive (𝑛 = 0)Negative (𝑛 = 23)
malaria, and it is mainly used in the screening of prospective
blood donors to avoid transfusion-transmitted malaria [17,
18]. A blood film should be taken from anyone whose
symptoms and history of travel suggest malaria. In clinical
practice, serology has no place in diagnosing acute malaria,
but in certain circumstances, it can be useful for better
understanding a possible history ofmalariawhennoparasites
have been found through microscopy, which is the gold
standard method for the diagnosis of malaria. That may
happen when a blood film from the subject was never
analysed or because they had taken antimalarial drugs at a
dosage sufficient to depress parasitemia to undetectable levels
before the contact with the malaria parasite. In such cases,
serological investigations may confirm or exclude malaria,
according to previous reports suggesting that an antibody
test is effective in detecting malaria infection in travellers
returning from overseas [19] and in nonimmune visitors to
endemic areas after their departure [19, 20].
Thirty-six out of 45 (80%) subjects from group 1 displayed
levels of anti-Plasmodium spp. antibodies when titrated
by a commercial immunoassay Malaria EIA kit, while the
remaining 9 (20%) subjects had no significant levels of anti-
Plasmodium spp. antibodies, when compared to the control
group (group no. 3). These 9 individuals might be at the
initial phase of infection or at an acute phase of the disease,
which would explain why no antibodies have been detected
in their serum, while they had microscopically positive slides
or a false positive microscopically. In any of these cases,
antibody levels are too low to be detected by this method
or have not been yet produced. On the other hand, 200
out of 335 (66%) subjects did not show significant levels
of anti-Plasmodium spp. antibodies with the commercial
kit used in this study. Moreover, 135 (40.29%) subjects had
significant levels of anti-Plasmodium spp. antibodies, when
compared to the control group (group no. 3). In our study,
the presence of antibodies in 34.1% of the subjects with
negative microscopy confirms the microscopy limitations,
and that an additional antibody test is an asset to know about
contact with malaria parasite in travellers from endemic
countries. Furthermore, it is often difficult to distinguish
between species, especially if the patient has already been
treated or has done chemoprophylaxis.
This work has been complemented with new studies that
evaluated the serological reactivity in these patients and were
identifiedmajor antigenic proteins that are responsible for the
production of the antibodies detected in this study [21].
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Figure 2: Distribution of antimalarial antibodies in subjects with possible clinical history of imported malaria. (a) (Group no. 1): individuals
who were potentially exposed to the parasites and have as a positive blood film diagnostic for malaria (𝑛 = 45). (b) (Group no. 2): subjects
potentially exposed to the parasite but have negative blood film diagnostic for malaria (𝑛 = 290). Group no. 3: control, healthy subjects
(𝑛 = 23).
4. Conclusions
This study showed that 40.29% of travellers with a pos-
sible history of malaria exposure were positive for anti-
Plasmodium spp. antibodies, while 40.29% of these individu-
als were negative by microscopy. The antibody test described
here is useful to elucidate malaria exposure in microscopy-
negative travellers from endemic countries.
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